argenx SE
IPOargenx | Homepage - Reaching Patients Through Immunology Innovation
Public · Amsterdam, Netherlands · Founded 2008 · $1.1B raised
- Headquarters
- Amsterdam
- Employees
- 501–1000
- Founded
- 2008
- Business Model
- B2B
- Website
- argenx.com
- Total Funding
- $1.1B
- Last Round
- $1.1B Growth EquityJul 2023
- Rounds
- 1
- Type
- Public
About
Global biopharmaceutical company developing antibody-based therapies for severe autoimmune diseases and cancer.
Summary
argenx SE is a Biotech company based in Amsterdam, Netherlands, founded in 2008. It has raised $1.1B in total across 1 round, most recently a $1.1B Growth Equity round in Jul 2023. Investors include Forbion Capital Partners.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jul 2023
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...